XLO
Xilio Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Xilio Therapeutics (XLO) Stock: Buy, Sell, or Hold?
$8.47
-0.06 (-0.70%)
âŧ
5d:
-2.76%
30d:
-8.13%
90d:
-5.99%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (55%)
Quality Score
36/100
Position
FAIR
30-Day Fair Range
$8.01 â $9.02
Position: FAIR
Forward P/E & Valuation
-4.3x
CHEAP
vs 23.0x historical avg
Wall Street Target
$18.00
+112.5% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$7.05 / $9.00
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: XLO is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Get Alerted When XLO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: XLO is currently trading at $8.47, which is considered fair relative to its 30-day fair value range of $8.01 to $9.02. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.3) compared to its historical average (23.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XLO is in a downtrend. Immediate support is located at $7.05, while resistance sits at $9.00.
Market Sentiment: XLO scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.00 (+112.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XLO is in a downtrend. Immediate support is located at $7.05, while resistance sits at $9.00.
Market Sentiment: XLO scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.00 (+112.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.01 -
$9.02
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
54.8%
Trading Range & Key Levels
30-Day Trading Range
$8.01 -
$9.02
Current vs Trading Range
FAIR
Support Level
$7.05
Resistance Level
$9.00
Current Trend
Downtrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 112.5% below Wall St target ($18.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-4.27
Wall Street Target
$18.00
(+112.5%)
Revenue Growth (YoY)
131.2%
Profit Margin
-34.1%
PE vs Historical
-4.3 vs 23.0
CHEAP
Share XLO Analysis
Share this live XLO analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (XLO)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Xilio Therapeutics announced the initiation of a Phase 1/2 clinical trial for XTX501, a PD-1/masked IL-2 bispecific, and provided pipeline and business updates.
Key Retail Themes:
Initiation of XTX501 Phase 1/2 clinical trial
Advancement of XTX602 and XTX701 towards IND filings
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 7:02 AM ET
Data refreshes hourly during market hours. Next update: 8:02 AM
Data refreshes hourly during market hours. Next update: 8:02 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XLO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$91 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 49 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$107 | 33 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive XLO Research Pages